-
Je něco špatně v tomto záznamu ?
S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is Not a Selective Inhibitor of Equilibrative Nucleoside Transporters but Also Blocks Efflux Activity of Breast Cancer Resistance Protein
S. Karbanova, A. Sorf, L. Jiraskova, A. Lalinska, Z. Ptackova, F. Staud, L. Cerveny,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
17-16169S
Grantová Agentura České Republiky
CZ.02.1.01/0.0/0.0/16_019/0000841
European Regional Development Fund
NLK
ProQuest Central
od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2010-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- ABC transportér z rodiny G, člen 2 antagonisté a inhibitory metabolismus MeSH
- antivirové látky metabolismus farmakokinetika MeSH
- biologický transport účinky léků MeSH
- buněčné linie MeSH
- buňky MDCK MeSH
- krysa rodu rattus MeSH
- lidé MeSH
- nádorové proteiny antagonisté a inhibitory metabolismus MeSH
- P-glykoproteiny antagonisté a inhibitory metabolismus MeSH
- placenta účinky léků metabolismus MeSH
- potkani Wistar MeSH
- psi MeSH
- těhotenství MeSH
- thioinosin analogy a deriváty farmakologie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- lidé MeSH
- psi MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is routinely used at concentrations of 0.10 μM and 0.10 mM to specifically inhibit transport of nucleosides mediated by equilibrative nucleoside transporters 1 (ENT1) and 2 (ENT2), respectively. We recently showed that NBMPR (0.10 mM) might also inhibit placental active efflux of [3H]zidovudine and [3H]tenofovir disoproxil fumarate. Here we test the hypothesis that NBMPR abolishes the activity of P-glycoprotein (ABCB1) and/or breast cancer resistance protein (ABCG2). METHODS: We performed accumulation assays with Hoechst 33342 (a model dual substrate of ABCB1 and ABCG2) and bi-directional transport studies with the ABCG2 substrate [3H]glyburide in transduced MDCKII cells, accumulation studies in choriocarcinoma-derived BeWo cells, and in situ dual perfusions of rat term placenta with glyburide. RESULTS: NBMPR inhibited Hoechst 33342 accumulation in MDCKII-ABCG2 cells (IC50 = 53 μM) but not in MDCKII-ABCB1 and MDCKII-parental cells. NBMPR (0.10 mM) also inhibited bi-directional [3H]glyburide transport across monolayers of MDCKII-ABCG2 cells and blocked ABCG2-mediated [3H]glyburide efflux by rat term placenta in situ. CONCLUSION: NBMPR at a concentration of 0.10 mM abolishes ABCG2 activity. Researchers using NBMPR to evaluate the effect of ENTs on pharmacokinetics must therefore interpret their results carefully if studying compounds that are substrates of both ENTs and ABCG2.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028483
- 003
- CZ-PrNML
- 005
- 20210114154017.0
- 007
- ta
- 008
- 210105s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11095-020-2782-5 $2 doi
- 035 __
- $a (PubMed)32086630
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Karbanova, Sara $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
- 245 10
- $a S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is Not a Selective Inhibitor of Equilibrative Nucleoside Transporters but Also Blocks Efflux Activity of Breast Cancer Resistance Protein / $c S. Karbanova, A. Sorf, L. Jiraskova, A. Lalinska, Z. Ptackova, F. Staud, L. Cerveny,
- 520 9_
- $a PURPOSE: S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is routinely used at concentrations of 0.10 μM and 0.10 mM to specifically inhibit transport of nucleosides mediated by equilibrative nucleoside transporters 1 (ENT1) and 2 (ENT2), respectively. We recently showed that NBMPR (0.10 mM) might also inhibit placental active efflux of [3H]zidovudine and [3H]tenofovir disoproxil fumarate. Here we test the hypothesis that NBMPR abolishes the activity of P-glycoprotein (ABCB1) and/or breast cancer resistance protein (ABCG2). METHODS: We performed accumulation assays with Hoechst 33342 (a model dual substrate of ABCB1 and ABCG2) and bi-directional transport studies with the ABCG2 substrate [3H]glyburide in transduced MDCKII cells, accumulation studies in choriocarcinoma-derived BeWo cells, and in situ dual perfusions of rat term placenta with glyburide. RESULTS: NBMPR inhibited Hoechst 33342 accumulation in MDCKII-ABCG2 cells (IC50 = 53 μM) but not in MDCKII-ABCB1 and MDCKII-parental cells. NBMPR (0.10 mM) also inhibited bi-directional [3H]glyburide transport across monolayers of MDCKII-ABCG2 cells and blocked ABCG2-mediated [3H]glyburide efflux by rat term placenta in situ. CONCLUSION: NBMPR at a concentration of 0.10 mM abolishes ABCG2 activity. Researchers using NBMPR to evaluate the effect of ENTs on pharmacokinetics must therefore interpret their results carefully if studying compounds that are substrates of both ENTs and ABCG2.
- 650 _2
- $a P-glykoproteiny $x antagonisté a inhibitory $x metabolismus $7 D018435
- 650 _2
- $a ABC transportér z rodiny G, člen 2 $x antagonisté a inhibitory $x metabolismus $7 D000070997
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antivirové látky $x metabolismus $x farmakokinetika $7 D000998
- 650 _2
- $a biologický transport $x účinky léků $7 D001692
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a psi $7 D004285
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a buňky MDCK $7 D061985
- 650 _2
- $a nádorové proteiny $x antagonisté a inhibitory $x metabolismus $7 D009363
- 650 _2
- $a placenta $x účinky léků $x metabolismus $7 D010920
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a thioinosin $x analogy a deriváty $x farmakologie $7 D013868
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sorf, Ales $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
- 700 1_
- $a Jiraskova, Lucie $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
- 700 1_
- $a Lalinska, Anezka $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
- 700 1_
- $a Ptackova, Zuzana $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
- 700 1_
- $a Staud, Frantisek $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
- 700 1_
- $a Cerveny, Lukas $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic. cervenyl@faf.cuni.cz.
- 773 0_
- $w MED00003779 $t Pharmaceutical research $x 1573-904X $g Roč. 37, č. 3 (2020), s. 58
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32086630 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114154014 $b ABA008
- 999 __
- $a ok $b bmc $g 1608818 $s 1119663
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 37 $c 3 $d 58 $e 20200221 $i 1573-904X $m Pharmaceutical research $n Pharm Res $x MED00003779
- GRA __
- $a 17-16169S $p Grantová Agentura České Republiky
- GRA __
- $a CZ.02.1.01/0.0/0.0/16_019/0000841 $p European Regional Development Fund
- LZP __
- $a Pubmed-20210105
